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Background: Faropenem (FRPM), the only penemused in Japan,
s known to have low inducibility to be resistant to antimicrobials.
n the present study, we investigated efﬁcacy of FRPM to acute
ncomplicated cystitis (AUC) and the optimal periods of admin-
stration with FRPM.
Methods: A randomized, open label, comparative multicen-
er study was conducted on female outpatients diagnosed with
UC at 35 participating institutions across Japan. The criteria to
ntry patients and the evaluation of efﬁcacy conformed to the
apanese Guidelines for Clinical Research of Antimicrobial Agents
n Urogenital Infections: the First Edition. FRPM with 200 mg,
.o. three times per day was administered to patients allocated to
ither the 3-day or 7-day administration group (target sample, 100
er group) using the central registration method; a registration
orm of entried patients were faxed and allocated by the clinical
rials ofﬁce (CREC Net, Kitakyushu, Japan). Bacteriological investi-
ation was conducted at Kyurin Corporation (Kitakyushu, Japan).
acteriological and clinical efﬁcacies were evaluated 5 to 9 days
ost-administration of FRPM.
Results: A total of 200 patients were registered between May
010 and May 2011 (3-day administration: n=97; median age, 49
ears old; age-range, 20-80 years. 7-day administration: n=103;
edian age, 47 years old; age-range, 21-81 years). Exclusion crite-
ia comprised insufﬁcient bacterial count at entry, lost to follow-up
nd withdrawal from the study. Microbiological outcome revealed
hat 7-day administration (n=64) was signiﬁcantly more effective
han 3-day administration (n=62) (eradication: 84.4% vs. 62.9%;
ersistence: 7.8% vs. 24.2%; replace: 7.8% vs. 12.9%; p=0.018). The
linical outcome tended to be greater in 7-day administration than
n 3-day administration, but differenceswere not signiﬁcant (82.6%
57/69] vs. 93.0% [(66/71]; p=0.061).Conclusion: Seven-day administration of FRPM (200mg, p.o.
hree timesperday)providesoptimal administration route forAUC.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.622fectious Diseases 16S (2012) e317–e473
Type: Poster Presentation
Final Abstract Number: 56.074
Session: Antibiotics
Date: Saturday, June 16, 2012
Time: 12:45-14:15
Room: Poster & Exhibition Area
Carbapenem therapy for bacteremia due to extended-spectrum
-lactamase-producing Escherichia coli or Klebsiella pneumo-
niae: Implications of Ertapenem susceptibility
P.-R. Hsueh1,∗, W.-C. Ko2
1 National Taiwan University Hospital, Taipei, Taiwan, R.O.C
2 National Cheng Kung University Medical College and Hospital,
Tainan, Taiwan, R.O.C
Background: Arbapenem susceptibility breakpoints for Enter-
obacteriaceae issued by the Clinical and Laboratory Standards
Institute (CLSI) had been recently revised and different from those
by the European Committee on Antimicrobial Susceptibility Test-
ing. Clinical impact of such a revision remains to be deﬁned.
Methods: A retrospective study evaluated patients treated with
a carbapenem for bacteremia caused by extended-spectrum beta-
lactamase (ESBL)-producing organisms at two medical centers in
Taiwan. Clinical characteristics, outcome, and risk factors of mor-
tality of these patients were analyzed.
Results: Of 251 patients with bacteremia treated by a car-
bapenem were identiﬁed. Among ESBL-producing E. coli and K.
pneumoniae, susceptibility rates of ertapenem were 83.8% and
76.4%, respectively, meropenem 100% and 99.3%, and imipenem
100% and 97.9%. The patients receiving inappropriate therapy
had a higher sepsis-related mortality than those with appropri-
ate therapy (P=0.002), irrespective of ertapenem, imipenem or
meropenem therapy. However, if the breakpoint of ertapenem sus-
ceptibility is 0.5 g/ml, the mortality of bacteremic episodes due
to isolates with MICs ≤0.5 g/ml is similar to those with MICs
>0.5 g/ml (P=0.8). Multivariate analysis of variables related to
sepsis-related mortality revealed that the presence of severe sep-
sis (odds ratio [OR], 9.70; 95% conﬁdence interval [CI], 3.15-29.86;
P <0.001), hospital-onset bacteremia (OR, 5.61; 95% CI, 1.64-19.13;
P=0.006), and ertapenem-nonsusceptible isolates (OR, 5.17; 95%
CI, 2.03-13.13; P=0.001) were independent risk factors.
Conclusion: Infections due to the causative isolates with
ertapenem MIC values ≤0.25 g/ml were associated with a favor-
able outcome if treated by a carbapenem. Such a ﬁnding supports
the rationale of the updated CLSI criteria of carbapenems for Enter-
obacteriaceae.
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Randomized clinical trial of mebendazole, metronidazol and
praziquantle in the treatment of giardiasis in Islamic Republic
of Iran 2008
R. Imani ∗, A. Khoshdellshahrekord medical university, Shahrekord, Iran, Islamic Republic of
Background: Giardia lamblia (G.L) is a common intestinal par-
asite associated with social or personal problems. Giardiasis is
